Lopinavir/ritonavir for high-grade anal disease in adults
Treatments studied
Part of Cancer clinical trials.
This early-phase study (Phase 1) tests how safe and tolerable the medicine lopinavir/ritonavir is for adults with HIV and biopsy-confirmed high-grade anal dysplasia. It may help find a possible treatment option for people at higher risk, while also checking for side effects and whether the study plan can be followed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have HIV and a biopsy-confirmed diagnosis of high-grade anal dysplasia (HGAIN)
- Be willing and able to sign informed consent
- Be able to follow the study visits and procedures
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an artesunate ointment to treat high-grade anal precancer (HSIL) in people who do not have HIV. The goal is to see if the ointment can clear the abnormal cells caused by HPV.
This study tests if a probiotic called EXE-346 can help clear anal high-grade squamous intraepithelial lesions (HSIL), a precancerous condition, in people with HIV who are on effective antiretroviral therapy. If you have anal HSIL that wasn't fully removed by biopsy, you may be able to join.
This study is looking at ways to screen for anal cancer in people who are at higher risk, such as those with weakened immune systems or a history of abnormal cells in the lower genital tract. It aims to find better methods for early detection.
This study tries to prevent anal cancer in men who have sex with men and are at higher risk due to HIV or PrEP use. It uses a special exam called high-resolution anoscopy to check for early signs.
This study tests a self-collected anal swab for detecting HPV (the virus that can cause anal cancer) in people living with HIV. It aims to see if this simple swab is as accurate as a doctor-collected sample, and may help prevent anal cancer.
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Hear when a new High-Grade Anal Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.